SWOG S1937

Primary Category:

Treatment Protocols

Disease Category:



Temporarily Closed

A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

S1937 is temporarily closed to accrual, effective May 30, 2023 at 12:00pm PST.

Eligible for screening study DCP 001